Teva Pharmaceutical Industries has earned a top Zacks Style Score for momentum, reflecting strong relative strength and positive price trends over the past three to six months. This ranking places Teva in the top 5% of all stocks tracked by Zacks, signaling to momentum investors that the company’s recent performance outpaces its industry peers and broader market benchmarks.

Teva’s specialty pipeline—anchored by AUSTEDO for chorea and tardive dyskinesia, UZEDY for persistent depressive disorder, and AJOVY for migraine prevention—now contributes over 40% of total revenue. Sequential quarterly growth in these therapies averaged 12%, with combined worldwide sales approaching $2.8 billion last year, underscoring Teva’s successful transition from a generics-focused business to a diversified specialty drug leader.

In a landmark deal, Royalty Pharma committed $500 million to Teva’s specialty R&D portfolio through a non-dilutive financing structure. This transaction validates Teva’s mid- to late-stage assets, accelerates pipeline advancement without equity issuance, and is expected to fund ongoing clinical trials for two Phase III candidates through 2027, reducing Teva’s capital outlay by approximately $120 million annually.

Teva currently trades below 12 times projected 2026 adjusted earnings, compared with an average 14x multiple for specialty pharmaceutical peers. Assuming execution on margin expansion targets—driven by cost synergies of $650 million by year-end—and continued specialty sales growth of 10–15% annually, a re-rating to peer multiples could unlock an additional 19–30% share price appreciation over the next 12–18 months.